What the trial was testing
The trial enrolled 124 patients with hepatitis b. The study was sponsored by Gilead Sciences and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Nearly 100% kept the virus suppressed after switching to tenofovir alafenamide.
The Lancet Gastroenterology & Hepatology · 2024 · NCT03180619
These findings — that after switching to tenofovir alafenamide in hepatitis B with kidney or liver impairment — were published in the The Lancet Gastroenterology & Hepatology and represent the headline result of the study.
Researchers tracked outcomes across 124 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with hepatitis b, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Tenofovir alafenamide (Vemlidy) is FDA-approved and available now for chronic hepatitis B. It is the preferred form when kidney or bone health is a concern. Ask a liver specialist about switching from older tenofovir disoproxil if you have kidney or bone issues.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open hepatitis b trials
Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.
A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B
This study will examine the safety and tolerability of single and multiple doses of IB-001, and will be conducted in two parts: Part A: SAD study in approximately 50 Healthy Volunteers (HV). Part B: MAD study in approximately 30 adult participants living with Chronic Hepatitis B (CHB).